Johnson & Johnson announced that the U.S. Food and Drug Administration has granted nipocalimab Breakthrough Therapy designation for the ...

The U.S. Food & Drug Administration has approved Johnson & Johnson's device for a type of condition which causes abnormal ...

Johnson & Johnson (J&J), formed in 1886, is a prominent American multinational corporation known for medical devices, pharmaceuticals, and consumer packaged goods.

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor model based on the published strategy ...

Guggenheim raised the firm’s price target on Johnson & Johnson to $162 from $156 and keeps a Neutral rating on the shares. The firm ...

In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other pharma stocks. Healthcare takes the concept of ‘defensive’ further than almost any ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor model based on the published strategy ...

Johnson & Johnson's robust pharmaceutical division drives growth amidst competitive challenges. Strategic divestitures and acquisitions shape JNJ's market presence and future prospects.

That was one New York Jets fan's wish on Halloween night, begging for Johnson, the Detroit Lions offensive coordinator and play-calling savant, to move to New York in 2025. The fan attending ...

Johnson & Johnson (NYSE:JNJ) lowered its full-year earnings outlook on Tuesday despite posting better-than-expected financials for Q3 2024, driven mainly by its pharma unit even as its MedTech ...

Good morning, and welcome to Johnson & Johnson's Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference.